FDA approves olezarsen as first treatment of familial chylomicronemia Dr. Kamal Kant Kohli23 Dec 2024 8:45 PM ISTThe US FDA has approved olezarsen (Tryngolza) as the first treatment for adults with familial chylomicronemia syndrome, a rare genetic condition...
Ionis announces positive results from Phase 2 study of ION224 to treat NASH/MASH Kajal Rajput17 March 2024 5:00 PM ISTNew Delhi: Ionis Pharmaceuticals announced positive results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor in...
AstraZeneca-Ionis Eplontersen granted USFDA fast track designation for transthyretin-mediated amyloid cardiomyopathy Ruchika Sharma10 Feb 2024 3:30 PM ISTCarlsbad: Ionis Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis...
AstraZeneca gets right to commercialize Eplontersen in Latin America Ruchika Sharma1 Aug 2023 1:30 PM ISTAstraZeneca paid Ionis USD 20 million to license eplontersen in Latin America.
AstraZeneca, Ionis Pharma seek US nod for Eplontersen after positive trial data Ruchika Sharma21 Jun 2022 3:35 PM ISTThe data from the 35-week interim analysis will be presented at an upcoming medical meeting later this year.
Pfizer, Ionis Pharma discontinue Vupanorsen Clinical Development Program Ruchika Sharma2 Feb 2022 2:01 PM ISTNew York: Pfizer Inc. and Ionis Pharmaceuticals, Inc. have recently announced the discontinuation of the Pfizer-led clinical development...
Ionis Eplontersen gets USFDA orphan drug designation Ruchika Sharma26 Jan 2022 10:30 AM ISTCarlsbad: Ionis Pharmaceuticals, Inc. has recently announced that the U.S. Food and Drug Administration (USFDA) has granted orphan drug...
AstraZeneca closes Eplontersen agreement with Ionis Medical Dialogues Bureau2 Jan 2022 10:00 AM ISTUK: AstraZeneca has announced that the company has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. for...
Pfizer initiates Phase 2b clinical study of vupanorsen, says Ionis, Akcea Ruchika Sharma5 Nov 2020 1:05 PM ISTCarlsbad and Boston: Ionis Pharmaceuticals, Inc. and its wholly owned subsidiary Akcea Therapeutics, Inc., have recently announced that Pfizer...
